$320 Million is the total value of ALTEGRIS ADVISORS, L.L.C.'s 17 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 92.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| QQQ | New | PowerShares QQQ Sep 104 Putput | $16,061,000 | – | 150,000 | +100.0% | 32.71% | – |
| AGNPRA | New | Allergan plc Pfd 5.5% 03/01/18pfd conv ser a | $3,910,000 | – | 3,750 | +100.0% | 7.96% | – |
| Jarden Corp 1 1/8% Due 3/15/2034 MS15note 1.125% 3/1 | $3,202,000 | -2.0% | 2,750,000 | 0.0% | 6.52% | -38.9% | ||
| FCAM | Sell | Fiat Chrysler Automobiles NV Convertible Pref 7.875%man cov sec 16 | $2,838,000 | -17.6% | 22,500 | -10.0% | 5.78% | -48.7% |
| Sell | Albany Molecular Research Inc Convertible 2 1/4% Due 11/15/2018 MN15note 2.250%11/1 | $2,796,000 | -2.4% | 2,000,000 | -11.1% | 5.70% | -39.2% | |
| VEREIT Inc Convertible 3% Due 8/1/2018 FA1note 3.000% 8/0 | $2,570,000 | -4.0% | 2,750,000 | 0.0% | 5.23% | -40.2% | ||
| Priceline Group Inc Convertible 0.35% Due 6/15/2020 JD15note 0.350% 6/1 | $2,495,000 | -2.8% | 2,250,000 | 0.0% | 5.08% | -39.5% | ||
| J2 Global Inc Convertible 3 1/4% Due 6/15/2029 JD15note 3.250% 6/1 | $2,319,000 | +0.7% | 2,000,000 | 0.0% | 4.72% | -37.3% | ||
| New | Canadian Solar Inc Convertible 4 1/4% Due 2/15/2019 FA15note 4.250% 2/1 | $2,204,000 | – | 2,250,000 | +100.0% | 4.49% | – | |
| New | Spectranetics Corp 2 5/8% Due 6/1/2034 JD1mtnf 2.625% 6/0 | $2,060,000 | – | 2,000,000 | +100.0% | 4.20% | – | |
| FTRPR | New | Frontier Communications Corppfd conv ser-a | $1,748,000 | – | 17,500 | +100.0% | 3.56% | – |
| New | Live Nation Entertainment Inc 2 1/2% Due 5/15/2019 MN15dbcv 2.500% 5/1 | $1,615,000 | – | 1,500,000 | +100.0% | 3.29% | – | |
| Sell | InvenSense Inc. Convertible 144A 1 3/4% Due 11/1/2018 MN1note 1.750%11/0 | $1,549,000 | -25.8% | 1,525,000 | -29.1% | 3.16% | -53.8% | |
| Sell | Infinera Corp 144A 1 3/4% Due 6/1/2018 JD1dbcv 1.750% 6/0 | $1,297,000 | -65.1% | 750,000 | -66.7% | 2.64% | -78.3% | |
| New | Workday Inc- Class A 1 1/2% Due 7/15/2020 JJ15note 1.500% 7/1 | $1,168,000 | – | 1,000,000 | +100.0% | 2.38% | – | |
| Buy | VEREIT Inc Convertible 3 3/4% Due 12/15/2020 JD15note 3.750%12/1 | $704,000 | +44.3% | 750,000 | +50.0% | 1.43% | -10.1% | |
| New | Workday Inc- Class A 0 3/4% Due 7/15/2018 JJ15note 0.750% 7/1 | $563,000 | – | 500,000 | +100.0% | 1.15% | – | |
| Exit | PowerShares QQQ May 15 104 Putput | $0 | – | -550 | -100.0% | -0.19% | – | |
| Exit | Omnicare Inc Convertible 3 1/2% Due 2/15/2044 FA15note 3.500% 2/1 | $0 | – | -1,500,000 | -100.0% | -5.96% | – | |
| Exit | Orexigen Therapeutics Inc. 144A 2 3/4% Due 12/1/2020 JD1note 2.750%12/0 | $0 | – | -2,000,000 | -100.0% | -7.53% | – | |
| ACTPRA | Exit | Actavis PLC Pfd 5.5% 03/01/18pfd conv ser a | $0 | – | -2,950 | -100.0% | -9.76% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-06
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QQQ US 11/18/16 P113 | 9 | Q3 2016 | 49.0% |
| ALBANY MOLECULAR RESH INC | 7 | Q2 2016 | 9.4% |
| INFINERA CORPORATION | 7 | Q2 2016 | 12.2% |
| VEREIT Inc Convertible 3% Due 8/1/2018 FA1 | 7 | Q3 2015 | 8.8% |
| Allergan Public Limited Company Preferred | 6 | Q3 2016 | 21.7% |
| VEREIT Inc Convertible 3 3/4% Due 12/15/2020 JD15 | 6 | Q3 2015 | 4.6% |
| Salesforce.com Inc Convertible 0 1/4% Due 4/1/2018 AO1 | 5 | Q3 2016 | 18.7% |
| Palo Alto Networks, Inc 144A Due 7/1/2019 At Mat | 5 | Q3 2016 | 11.1% |
| NXP SEMICONDUCTORS N V | 4 | Q3 2016 | 15.7% |
| PRICELINE GRP INC | 4 | Q4 2015 | 9.6% |
View ALTEGRIS ADVISORS, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-04-02 |
| 13F-NT | 2024-02-14 |
| 13F-NT | 2023-11-09 |
| 13F-NT | 2023-08-10 |
| 13F-NT | 2023-05-09 |
| 13F-NT | 2023-02-15 |
| 13F-NT | 2022-10-28 |
| 13F-NT | 2022-07-26 |
| 13F-NT | 2022-05-11 |
| 13F-NT | 2022-02-04 |
View ALTEGRIS ADVISORS, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.